Atossa Therapeutics, Inc. Common Stock (ATOS) Stock Price

ATOSStock

$2.68−77.36%52W

Market Cap$26.74M

P/E—

PEG Ratio—

Div yield—

Beta1.24

ATOS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-50.42%

Price vs S&P 500 (4W)6.26%

VGM Score21.08

Book Value / Share (Quarterly)$2.69

P/TBV (Annual)1.47x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.59

Price vs S&P 500 (YTD)-82.13%

Gross Margin (TTM)62.50%

Net Profit Margin (TTM)-7412.50%

EPS (TTM)$-4.34

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-4.34

EPS (Annual)$-4.04

ROI (Annual)-88.35%

Gross Margin (Annual)100.00%

Cash / Share (Quarterly)$2.61

ROA (Last FY)-73.03%

EBITD / Share (TTM)$-4.52

ROE (5Y Avg)-38.97%

Operating Margin (TTM)-7412.50%

Cash Flow / Share (Annual)$-3.46

P/B Ratio0.93x

P/B Ratio (Quarterly)0.72x

Net Income / Employee (Annual)$-2,483,600

EV / Revenue (TTM)-7.16x

Net Interest Coverage (TTM)-507.00x

ROA (TTM)-85.78%

EPS Incl Extra (Annual)$-4.04

Current Ratio (Annual)5.53x

Quick Ratio (Quarterly)4.81x

3-Month Avg Trading Volume0.13M

52-Week Price Return-77.36%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.09

P/S Ratio (Annual)623.71x

Asset Turnover (Annual)0.00x

52-Week High$19.35

EPS Excl Extra (Annual)$-4.04

CapEx CAGR (5Y)18.13%

Tangible BV CAGR (5Y)123.11%

26-Week Price Return-39.17%

Quick Ratio (Annual)5.03x

13-Week Price Return-46.88%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.69x

Enterprise Value$-1.15M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)51.61%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-30425.00%

Cash / Share (Annual)$4.80

3-Month Return Std Dev108.56%

Net Income / Employee (TTM)$-2,693,500

ROE (Last FY)-88.35%

Net Interest Coverage (Annual)-94.50x

EPS Basic Excl Extra (Annual)$-4.04

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.34

Receivables Turnover (Annual)6.30x

ROI (TTM)-102.99%

P/S Ratio (TTM)155.93x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.09

Price vs S&P 500 (52W)-95.67%

Year-to-Date Return-70.17%

5-Day Price Return1.93%

EPS Normalized (Annual)$-4.04

ROA (5Y Avg)-34.82%

Net Profit Margin (Annual)-36650.00%

Month-to-Date Return27.54%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-4.31

Operating Margin (Annual)-30425.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-38.97%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.34

P/TBV (Quarterly)1.47x

P/B Ratio (Annual)1.94x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-7412.50%

Book Value / Share (Annual)$4.57

Price vs S&P 500 (13W)-49.68%

Beta1.24x

Revenue / Share (TTM)$0.00

ROE (TTM)-102.99%

52-Week Low$1.70

mGradeD

vgmGradeD

ATOS Earnings Surprise History

Q2 25-1.05est. -0.85

Q3 25-1.05est. -1.00

Q4 25-1.34est. -1.14

Q1 26-1.11est. -1.22

Q2 26-0.95est. -1.10

ATOS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATOSAtossa Therapeutics, Inc. Common Stock	—	—	D	$2.68
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Atossa Therapeutics, Inc. Common Stock

Atossa Therapeutics is a clinical-stage biopharmaceutical company developing treatments for breast cancer and COVID-19. Its lead candidate, Endoxifen, targets breast cancer and related breast conditions. The company also has two COVID-19 programs in development: AT-H201, an inhaled therapy for hospitalized patients, and AT-301, a nasal spray for at-home use.